JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on December 30, 2004; DOI: 10.1124/jpet.104.078808


0022-3565/05/3131-333-344$20.00
JPET 313:333-344, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.078808v1
313/1/333    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hsu, Y.-L.
Right arrow Articles by Lin, C.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hsu, Y.-L.
Right arrow Articles by Lin, C.-C.

CELLULAR AND MOLECULAR

Asiatic Acid, a Triterpene, Induces Apoptosis and Cell Cycle Arrest through Activation of Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Pathways in Human Breast Cancer Cells

Ya-Ling Hsu, Po-Lin Kuo, Liang-Tzung Lin, and Chun-Ching Lin

Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan (Y.-L.H., C.-C.L.); Department of Biotechnology, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan (P.-L.K.); and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada (L.-T.L.)

This study first investigates the anticancer effect of asiatic acid in two human breast cancer cell lines, MCF-7 and MDA-MB-231. Asiatic acid exhibited effective cell growth inhibition by inducing cancer cells to undergo S-G2/M phase arrest and apoptosis. Blockade of cell cycle was associated with increased p21/WAF1 levels and reduced amounts of cyclinB1, cyclinA, Cdc2, and Cdc25C in a p53-independent manner. Asiatic acid also reduced Cdc2 function by increasing the association of p21/WAF1/Cdc2 complex and the level of inactivated phospho-Cdc2 and phospho-Cdc25C. Asiatic acid treatment triggered the mitochondrial apoptotic pathway indicated by changing Bax/Bcl-2 ratios, cytochrome c release, and caspase-9 activation, but it did not act on Fas/Fas ligand pathways and the activation of caspase-8. We also found that mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK1/2), and p38, but not c-Jun NH2-terminal kinase (JNK), are critical mediators in asiatic acid-induced cell growth inhibition. U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] or SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole], specific inhibitors of mitogen-activated protein kinase kinase and p38 kinase activities, significantly decreased or delayed apoptosis. Asiatic acid was likely to confine the breast cancer cells in the S-G2/M phase mainly through the p38 pathway, because both SB203580 and p38 small interfering RNA (siRNA) inhibition significantly attenuated the accumulation of inactive phospho-Cdc2 and phospho-Cdc25C proteins and the cell numbers of S-G2/M phase. Moreover, U0126 and ERK siRNA inhibition completely suppressed asiatic acid-induced Bcl-2 phosphorylation and Bax up-regulation, and caspase-9 activation. Together, these results imply a critical role for ERK1/2 and p38 but not JNK, p53, and Fas/Fas ligand in asiatic acid-induced S-G2/M arrest and apoptosis of human breast cancer cells.


Received October 3, 2004; accepted December 22, 2004.

Address correspondence to: Professor Chun-Ching Lin, Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd., Kaohsiung 807, Taiwan, Republic of China. E-mail: aalin{at}ms24.hinet.net




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
R. Vasilcanu, D. Vasilcanu, B. Sehat, S. Yin, A. Girnita, M. Axelson, and L. Girnita
Insulin-Like Growth Factor Type-I Receptor-Dependent Phosphorylation of Extracellular Signal-Regulated Kinase 1/2 but not Akt (Protein Kinase B) Can Be Induced by Picropodophyllin
Mol. Pharmacol., March 1, 2008; 73(3): 930 - 939.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Zhang, S. Wang, S. Kern, X. Cui, and R. L. Danner
Nitric Oxide Down-regulates Polo-like Kinase 1 through a Proximal Promoter Cell Cycle Gene Homology Region
J. Biol. Chem., January 12, 2007; 282(2): 1003 - 1009.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. Calcabrini, J. M. Garcia-Martinez, L. Gonzalez, M. J. Tendero, M. T. A. Ortuno, P. Crateri, A. Lopez-Rivas, G. Arancia, P. Gonzalez-Porque, and J. Martin-Perez
Inhibition of proliferation and induction of apoptosis in human breast cancer cells by lauryl gallate
Carcinogenesis, August 1, 2006; 27(8): 1699 - 1712.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. Yamaguchi, S.-H. Lee, T. E. Eling, and S. J. Baek
A novel peroxisome proliferator-activated receptor {gamma} ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1352 - 1361.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Khan, S. Varadharaj, L. P. Ganesan, J. C. Shobha, M. U. Naidu, N. L. Parinandi, S. Tridandapani, V. K. Kutala, and P. Kuppusamy
C-phycocyanin protects against ischemia-reperfusion injury of heart through involvement of p38 MAPK and ERK signaling
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2136 - H2145.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.